These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2113850)

  • 1. Intermittent GnRH antagonist plus progestin contraception conserving tonic ovarian estrogen secretion and reducing progestin exposure.
    Danforth DR; Williams RF; Hsiu JG; Roh SI; Hahn D; McGuire JL; Hodgen GD
    Contraception; 1990 Jun; 41(6):623-31. PubMed ID: 2113850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
    Heikinheimo O; Gordon K; Williams RF; Hodgen GD
    Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovulation inhibition by administration of weekly gonadotropin-releasing hormone antagonist.
    Kenigsberg D; Hodgen GD
    J Clin Endocrinol Metab; 1986 Apr; 62(4):734-8. PubMed ID: 3081571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM; Nestor JJ; Vickery BH
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human.
    Hall JE; Bhatta N; Adams JM; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1991 May; 72(5):993-1000. PubMed ID: 1902489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function.
    Zelinski-Wooten MB; Lanzendorf SE; Wolf DP; Chandrasekher YA; Stouffer RL
    J Clin Endocrinol Metab; 1991 Sep; 73(3):577-83. PubMed ID: 1908481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of high dose gonadotrophin-releasing hormone antagonist treatment during the late follicular phase in the macaque abolishes luteal function irrespective of effects upon the luteinizing hormone surge.
    Fraser HM; Lunn SF; Morris KD; Deghenghi R
    Hum Reprod; 1997 Mar; 12(3):430-5. PubMed ID: 9130734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
    Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
    J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
    Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
    Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible protocol for administration of human follicle-stimulating hormone with gonadotropin-releasing hormone antagonist.
    Byrd S; Itskovitz J; Chillik C; Hodgen GD
    Fertil Steril; 1992 Jan; 57(1):209-14. PubMed ID: 1730319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women.
    Roseff SJ; Kettel LM; Rivier J; Burger HG; Baulieu E; Yen SS
    Fertil Steril; 1990 Nov; 54(5):805-10. PubMed ID: 2226914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rhesus monkey corpus luteum is dependent on pituitary gonadotropin secretion throughout the luteal phase of the menstrual cycle.
    Hutchison JS; Zeleznik AJ
    Endocrinology; 1984 Nov; 115(5):1780-6. PubMed ID: 6436009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
    Hall JE; Whitcomb RW; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.